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CASE REPORT
Patient K.F., a 32-year-old woman, was vaccinated with rubella vaccine (HPV-77 DE5 strain)* one day after delivering her first child, a boy, on September 5, 1975, and was advised to use contraceptives for the next three months. She breast-fed her child from the first day of birth till 12 months of age. Twelve days after vaccination, she developed painless, nontender cervical adenopathy and a maculopapular rash over the face and on the arms and legs that lasted for two days. She had no fever or other complaint. Breast milk, blood, and a throat swab from the mother and a throat swab from her infant were obtained on the first day of maternal rash. Additional selected specimens were collected during the subsequent 15 months.
Abbreviations used
HAl: hemagglutination inhibition antibody titer CMI: cell-mediated immunity LT:
lymphocyte transformation
MATERIALS AND METHODS
Rubella virus isolation was attempted in African green monkey kidney cells using the interference technique with Echovirus, type 11. Confirmation of isolates as rubella virus was accomplished using rubella specific rabbit antiserum. The HAI antibody titers were determined according to Center of Disease Control protocol? Immunoglobulin fractionation of sera and milk was done by ultracentrifugation in a continuous sucrose gradient. The 12 fractions collected by puncture of the centrifuge tube were tested for rubella antibody by HAI titration. With this method, no pretreatment for removal of beta lipoprorein inhibitors is required. Rubella specific cell-mediated immunity was measured by uptake of 14C-thymidine in Ficoll-Hypaque purified lymphocyte cultures obtained from heparinized blood. Cultures stimulated with a purified rubella virus antigen, with a purified noninfected cell antigen and with non-stimulated cultures were tested *The rubella vaccine HPV-77 DE~ strain used in this study is marketed as Meruvax by Merck, Sharp & Dohme.
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in parallel. 4 Results of lymphocyte transformation after rubella virus antigen stimulation are expressed as the ratio between 14C-thymidine uptake in virus-stimulated and nonstimulated lymphocyte cultures.
RESULTS AND COMMENTS
On the twelfth day after vaccination, when the mother noted rash and adenopathy, rubella virus was isolated from her breast milk and from her infant's throat swab specimen (Table I) . Virus was not isolated from the mother's throat swab. Virus isolated from the infant's throat swab was probably ingested.
Although the ingested rubella vaccine did not provoke a detectable serologic response in the infant as measured by HAI with treated serum or sucrose gradient separated IgG fractions, it did stimulate a significant level of rubella specific CMI. The infant's stimulation ratio with rubella virus was 6 on Day 35 (Table I ) and close to unity with control antigen prepared from uninfected cells. This observation is consistent with previous work which has demonstrated sensitization of T lymphocytes prior to that of B lymphocytes. Primary serologic response, as measured by HA1 antibody is not detected until at least 14 days after rubella vaccination, whereas CMI measured by leukocyte migration inhibitory factor ~ and by LT ~ has been detected seven to ten days after vaccination.
Absence of IgM two weeks after the child received rubella vaccine (HPV-77 DE~ strain) at age one year is consistent with a secondary rather than a primary type vaccine response. Multiple testing for IgM at more frequent intervals was not possible. Vaccination, however, stimulated a renewed increase in the CMI response of the child from a stimulation ratio of 3.7 to 7. This increase, according to our experience, is consistent with a booster type response.
We have failed to isolate rubella virus in breast milk from two women who received RA27/3 strain of rubella vaccine in the immediate postpartum period. In previous trials of rubella vaccines during which throat swabs specimens were collected on a daily basis, it was well documented that pharyngeal shedding occurred for only a few days and at relatively low titer. 7 In.the cases reported here, study of breast milk collected at such frequent intervals was not practical.
This report documents, for the first time, that breastfeeding after postpartum rubella vaccine immunization Can provide exposure to vaccine virus for the young infant. This exposure was not accompanied by any untoward effect; maternal postpartum immunization should be continued whenever necessary. Additional studies of the immune responses of infants exposed by this procedure to vaccine virus during the neonatal period may yield rewarding information concerning developmental immunology.
